Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

Triple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer. Owing to the absenteeism of hormonal receptors expressed at the cancerous breast cells, hormonal therapies and other medications targeting human epidermal growth factor receptor 2 (HER2) are ineffective in TNB...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattab, Dima, Bakhtiar, Athirah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599839/
https://www.ncbi.nlm.nih.gov/pubmed/33003468
http://dx.doi.org/10.3390/pharmaceutics12100929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599839/
https://www.ncbi.nlm.nih.gov/pubmed/33003468
http://dx.doi.org/10.3390/pharmaceutics12100929

Ejemplares similares